Articles

First RAS Inhibitor Extends Survival in Metastatic Pancreatic Cancer

Daraxonrasib, the first RAS inhibitor, has received FDA approval, extending survival in metastatic pancreatic adenocarcinoma. This article outlines key updates and implications for stakeholders.

Mass General Brigham's Life-Saving Claims: A Closer Look

Mass General Brigham claims to be saving more lives, but some doctors express skepticism. This article explores the implications for the pharmaceutical industry.

Immunovant Shares Surge on Arthritis Trial Data: What It Means for Pharma

Immunovant's recent trial data has led to a significant surge in its shares. This article explores the implications for pharmaceutical teams and investors.

RFK Jr.’s Screen Time Warning: Implications for Pharma

RFK Jr. raises concerns about screen time. This article examines the implications for pharmaceutical teams and the industry at large.

Eli Lilly's $200M Fraud Allegations: Implications for Pharma

Eli Lilly has accused church-linked pharmacies and wholesalers of a massive rebate fraud scheme involving Trulicity. This article explores the implications for the pharma industry.

RA Capital Secures $75M for Biotech SPAC: Implications for Pharma

RA Capital's recent $75M investment in a biotech SPAC raises questions about future trends in the pharmaceutical sector. This article explores its implications for industry stakeholders.

Guarding Biotech from China: Big Bets in Longevity

This article examines the strategic measures to protect biotech from Chinese influence and the growing investments in longevity research.

Covert Campaign: Biotechs vs. FDA Commissioner

This article delves into the covert campaign by a group of biotechs aimed at pushing out the FDA commissioner, exploring its implications for the pharmaceutical industry.

BioMarin's Study Success: Implications for Pharma Expansion

BioMarin Pharmaceutical has achieved a significant milestone in its latest study, potentially expanding the use of its top-selling medicine. This article explores the implications for the pharmaceutical industry.

BioMarin's Strategic Move: Voxzogo Label Expansion Insights

BioMarin Pharmaceutical aims to expand Voxzogo's label following a successful trial. This article analyzes the competitive implications for pharma teams.

Incyte's Strategic AI Partnerships: Implications for Pharma

Incyte has signed significant AI deals with Genesis Molecular AI and Edison Scientific, marking a pivotal moment for its innovation strategy. This article explores the implications for the pharmaceutical landscape.

NIH Infectious Disease Institute Leadership Change: Implications for Pharma

The acting head of the NIH’s infectious disease institute has stepped down, raising questions about future directions in infectious disease research and funding.

Elevance Executive Testifies in Medicare Advantage Fraud Case

Elevance's executive faces deposition in a Medicare Advantage fraud case, raising critical implications for the pharmaceutical industry.

BMS Expands in Texas While Novartis Faces Tenant Challenges

Bristol Myers Squibb is planning a new campus in Texas, while Novartis is facing eviction issues with a tenant in Slovenia. These developments could reshape the competitive landscape.

BioMarin Seeks Approval for Voxzogo in Short Stature Indication

BioMarin Pharmaceutical is pursuing further approval for Voxzogo to treat short stature. This article explores the implications for investors and pharma teams.

Senate Committee Questions NIH Director on 2027 Budget: Key Insights

The Senate committee's questioning of the NIH director sheds light on the 2027 budget, raising important considerations for the pharmaceutical industry.

China's Drugmakers Shine at ASCO26: Key Insights

China's drugmakers are set to make a significant impact at ASCO26. This article explores the implications for the pharmaceutical industry and investment opportunities.

Bristol Myers' Innovative Approach to Alzheimer's Beyond Amyloid

Bristol Myers is exploring innovative approaches to Alzheimer's treatment that extend beyond amyloid. This article delves into the implications for the pharmaceutical industry.

Gilead's Commitment to Combat Visceral Leishmaniasis with AmBiosome

Gilead Sciences has pledged 400,000 doses of AmBiosome to fight visceral leishmaniasis in partnership with the WHO. This initiative marks a significant step in addressing this neglected tropical disease.

How Florida Hospitals Secured Medicaid Funds: A Strategic Overview

Florida hospitals have successfully secured significant Medicaid funding, impacting the healthcare landscape. This article explores the implications for pharmaceutical stakeholders.